On Monday, Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) was 8.17% up from the session before settling in for the closing price of $40.99. A 52-week range for CRNX has been $24.10 – $62.53.
During the last 5-year period, the sales drop of Healthcare Sector giant was -12.11%. When this article was written, the company’s average yearly earnings per share was at -29.45%. With a float of $87.11 million, this company’s outstanding shares have now reached $94.13 million.
Crinetics Pharmaceuticals Inc (CRNX) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Crinetics Pharmaceuticals Inc stocks. The insider ownership of Crinetics Pharmaceuticals Inc is 7.50%, while institutional ownership is 107.85%. The most recent insider transaction that took place on Oct 01 ’25, was worth 209,050. In this transaction Chief Med and Dev Officer of this company sold 5,000 shares at a rate of $41.81, taking the stock ownership to the 66,270 shares. Before that another transaction happened on Oct 01 ’25, when Company’s Officer proposed sale 5,000 for $41.65, making the entire transaction worth $208,250.
Crinetics Pharmaceuticals Inc (CRNX) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.96 earnings per share (EPS) during the time that was less than consensus figure (set at -0.91) by -0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.28 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -29.45% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.29% during the next five years compared to -12.11% drop over the previous five years of trading.
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Trading Performance Indicators
You can see what Crinetics Pharmaceuticals Inc (CRNX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 17.80. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3004.14.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.11, a number that is poised to hit -1.24 in the next quarter and is forecasted to reach -5.00 in one year’s time.
Technical Analysis of Crinetics Pharmaceuticals Inc (CRNX)
Looking closely at Crinetics Pharmaceuticals Inc (NASDAQ: CRNX), its last 5-days average volume was 1.22 million, which is a jump from its year-to-date volume of 1.1 million. As of the previous 9 days, the stock’s Stochastic %D was 31.63%.
During the past 100 days, Crinetics Pharmaceuticals Inc’s (CRNX) raw stochastic average was set at 85.77%, which indicates a significant increase from 72.29% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.99 in the past 14 days, which was higher than the 1.54 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $37.36, while its 200-day Moving Average is $33.80. However, in the short run, Crinetics Pharmaceuticals Inc’s stock first resistance to watch stands at $45.55. Second resistance stands at $46.77. The third major resistance level sits at $48.99. If the price goes on to break the first support level at $42.11, it is likely to go to the next support level at $39.89. Should the price break the second support level, the third support level stands at $38.67.
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Key Stats
There are 94,176K outstanding shares of the company, which has a market capitalization of 4.18 billion. As of now, sales total 1,040 K while income totals -298,410 K. Its latest quarter income was 1,030 K while its last quarter net income were -115,640 K.
